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SUMMARY
US cholera surveillance offers insight into global and domestic trends. Between 2001 and 2011, 
111 cases were reported to the Centers for Disease Control and Prevention. Cholera was 
associated with international travel in 90 (81%) patients and was domestically acquired in 20 
(18%) patients; for one patient, information was not available. From January 2001 to October 
2010, the 42 (47%) travel-associated cases were associated with travel to Asia. In October 2010, a 
cholera epidemic started in Haiti, soon spreading to the Dominican Republic (Hispaniola). From 
then to December 2011, 40 (83%) of the 48 travel-associated cases were associated with travel to 
Hispaniola. Of 20 patients who acquired cholera domestically, 17 (85%) reported seafood 
consumption; 10 (59%) ate seafood from the US Gulf Coast. In summary, an increase in travel-
associated US cholera cases was associated with epidemic cholera in Hispaniola in 2010–2011. 
Travel to Asia and consumption of Gulf Coast seafood remained important sources of US cholera 
cases.
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INTRODUCTION
Cholera continues to ravage populations in many developing countries, most recently in 
Haiti and the Dominican Republic, the two countries that form the island of Hispaniola [1, 
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2], although cholera transmission and effective measures for its prevention have been 
understood for over 150 years [3, 4]. For over a century, most cases of cholera identified in 
the United States have been associated with travel to countries with endemic cholera [5–9]. 
Domestically acquired cases are primarily associated with the consumption of raw or 
undercooked seafood harvested from the US Gulf Coast [10–12]. Periodic reviews of US 
cholera surveillance offer a window on the global cholera situation; this report summarizes 
cholera cases diagnosed in the United States during 2001–2011.
METHODS
Cases of cholera that occur in the United States are reported by state and local health 
departments to the Centers for Disease Control and Prevention (CDC) via the Cholera and 
Other Vibrio Illness Surveillance (COVIS) system [13]. CDC requests isolates from all 
suspected cases for confirmatory testing. A confirmed case of cholera is defined as an illness 
characterized by diarrhea, vomiting, or both with (1) isolation of toxigenic Vibrio cholerae 
serogroup O1 or O139 from stool or vomitus or (2) serological evidence of recent O1 
infection, defined as a vibriocidal antibody titre ≥640 in acute or early convalescent phase 
sera in a person epidemiologically linked to a confirmed cholera case. Data reported to 
COVIS include demographic, clinical, and exposure information, including domestic and 
international travel and seafood consumption within 7 days of illness onset. A travel-
associated case is defined as cholera in a person who travelled outside the United States 
during the 7 days before illness onset; cases in persons who report no such travel are 
considered domestically acquired, and cases in persons for whom information about travel is 
not available are categorized as unknown. If more than one destination country is reported, 
exposure is assumed to have occurred where cholera is currently circulating. Cases reported 
to COVIS with onset from 1 January 2001 to 31 December 2011 were included in this 
review.
All V. cholerae serogroup O1 and O139 isolates are confirmed on the basis of agglutination 
in specific antiserum. Boiled lysates of V. cholerae are amplified by polymerase chain 
reaction (PCR) to detect the presence of cholera toxin (ctxA) [14], biotype-specific (tcpA) 
genes [15], and species-specific gene sequences (ompW, toxR) [16, 17]. Molecular subtyping 
by pulsed-field gel electrophoresis (PFGE) is conducted [18]. The resulting PFGE patterns 
are analysed using BioNumerics software (Applied Maths, USA) and uploaded to the Vibrio 
cholerae National PulseNet database where comparisons to previously reported V. cholerae 
isolates are conducted. PulseNet is the national molecular subtyping network for foodborne 
bacterial pathogens. Susceptibility testing of toxigenic V. cholerae isolates is performed by 
the disk diffusion method for the following antimicrobials: kanamycin (included in testing 
until 2010), amoxicillin-clavulanate (included in testing beginning in 2010 for patients who 
reported travel to Haiti), ampicillin, chloramphenicol, ciprofloxacin, furazolidone, nalidixic 
acid, streptomycin, sulfisoxazole, trimethoprim-sulfamethoxazole and tetracycline, in 
accordance with Clinical Laboratory Standards Institute (CLSI) recommendations [19, 20]. 
Escherichia coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 were used as 
internal quality controls. Interpretive criteria specific for V. cholerae were applied when 
available [19], or CLSI criteria for Enterobacteriaceae were used [20].
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Demographic and clinical information
COVIS received reports of 111 confirmed cases of cholera diagnosed in the United States 
between 1 January 2001 and 31 December 2011. Cases were reported by 27 states and two 
territories (Fig. 1) with onset dates ranging from 7 April 2001 to 21 November 2011 (Fig. 2). 
A marked increase in reports occurred after epidemic cholera began in Haiti in October 
2010; 46% of all cases over the 11-year study period were reported in the subsequent 14 
months.
Fifty-six patients (50%) were female. Patients’ median age was 44 years (range 1–85 years); 
nine (8%) were aged <10 years, 95 (86%) were 10–64 years and 17 (15%) were ≥65 years 
(Table 1). Of the 111 patients, 109 (98%) reported diarrhoea, and 52 (47%) reported 
vomiting. Other reported symptoms included abdominal cramps (52%), nausea (46%), fever 
(14%), muscle aches (13%), headache (11%), and blood in stool (5%). Of the 90 patients 
with available information, 56 (62%) were hospitalized. In hospitalized patients with severe 
complications, four (4%) patients had acute renal failure, two (2%) had cardiopulmonary 
arrest, and one (1%) had shock; none died. In all, 81 (73%) patients received an 
antimicrobial agent for treatment.
Exposures (source of illness)
Travel-associated cases—In 90 (81%) patients, cholera was travel-associated. Travel to 
Hispaniola accounted for 40 (44%) cases (Haiti, 29; Dominican Republic, 11), to South Asia 
for 35 (39%) cases (India, 17; Pakistan, 13; Bangladesh, 4; Nepal, 1), to Southeast Asia for 
13 (14%) cases (Philippines, 8; Indonesia, 3; Thailand, 2); and to West Africa for two (2%) 
cases (Ghana, 1; Benin, 1). The 42 travel-associated cases with onset from January 2001 to 
21 October 2010 were all associated with travel to South and Southeast Asia. After 21 
October 2010, 40 (83%) of the 48 travel-associated cases were associated with travel to 
Hispaniola.
Travel-associated cases were reported by 27 states. Most of the 40 cases associated with 
travel to Hispaniola were reported by Florida (14 cases) and New York (12 cases); 10 other 
states reported the other 14 cases associated with travel to Hispaniola. The 49 cases 
associated with travel to destinations other than Hispaniola were more widely distributed 
across the United States, with 22 states reporting cases with no more than eight reports from 
a single state.
Reported reasons for travel included visiting friends and relatives (62%, including nine who 
attended a wedding in the Dominican Republic on 22 January 2011 [21]), tourism (7%), 
business (7%), medical missions or other relief work (9%, most with travel to Hispaniola), 
and immigration to the United States (5%); information on the reason for travel was not 
available for 12%.
Domestically acquired cases—Twenty (18%) domestically acquired cases were 
reported by seven states and one territory; 19 (95%) reported seafood consumption. Ten 
(50%) were associated with consumption of Gulf Coast seafood; seven of these patients 
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resided in Louisiana. Gulf Coast seafood consumed included: raw oysters (two cases), 
boiled and/or raw crabs (eight cases), cooked shrimp (five cases), and fish (three cases). The 
other 10 (50%) domestically acquired cases included six patients with a history of non-Gulf 
Coast seafood consumption for whom the source of seafood was not known, three patients 
with a history of imported seafood consumption (reheated conch imported from Haiti for 
one, fried shrimp imported from either Nicaragua or Indonesia for one, and raw shrimp 
imported from Asia for one) and one patient who reported eating no seafood (a young child 
whose source was unclear but who had contact with travellers from Pakistan). Of the 19 
patients with domestically acquired cholera who reported seafood consumption, eight (47%) 
consumed the seafood raw.
Unknown source—One (1%) patient was lost to follow-up, so no information about 
either the location or the likely source of exposure was available.
Laboratory results
Cholera was confirmed by isolation of toxigenic V. cholerae from stool in 108/111 cases; 
107 (96%) stool specimens yielded V. cholerae serogroup O1, all biotype El Tor; 22 (21%) 
were serotype Inaba, and 85 (79%) were serotype Ogawa (Table 2). One (1%) stool 
specimen collected in 2009 yielded sero-group O139; the patient had domestically acquired 
cholera and reported consuming imported raw shrimp purchased from a seafood market 
specializing in Asian foods. Three cases (3%, all in patients with a history of travel to 
Hispaniola) were confirmed serologically.
PFGE results were available for 93 (87%) V. cholerae isolates (Table 2). The PFGE pattern 
combinations of 45 (48%) serogroup O1 isolates were indistinguishable from isolates 
obtained from patients in Hispaniola, [21, 22] labelled the ‘Haiti pattern’. Of these 45 
patients, 26 (60%) reported travel to Haiti, 10 (22%) to the Dominican Republic, five (11%) 
to India, one to Pakistan (2%), one (2%) to Benin; two (4%) reported no travel but 
consumed imported seafood (from Haiti for one and from either Indonesia or Nicaragua for 
the other). The PFGE pattern combinations of nine (10%) serogroup O1 isolates from 
patients with domestically acquired cholera associated with exposure to seafood from the 
Gulf Coast, labeled the ‘Gulf Coast strain,’ were indistinguishable from each other and from 
the established pattern of the Gulf Coast strain [23]. Of the remaining 39 serogroup O1 
isolates, labelled ‘Other patterns’, 23 reported travel to South Asia [nine (39%) each to India 
and Pakistan, four (17%) to Bangladesh, and one (4%) to Nepal]; eight to Southeast Asia 
[five (63%) to the Philippines) and three (38%) to Indonesia]; five reported no travel; and 
one had unknown exposure, but was a resident of Guam. The PFGE pattern of the serogroup 
O139 isolate was similar but not identical to PFGE patterns of serogroup O1 and O139 
isolates from patients who had travelled to countries in Southeast Asia.
Antimicrobial susceptibility testing was conducted on all 107 V. cholerae O1 isolates and 
defined three major antibiotic susceptibility pattern complexes (Table 2). The first is a pan-
susceptibility pattern, in which isolates were susceptible to all antimicrobial agents tested. 
This pattern was seen only in the 10 isolates from patients whose source of infection was 
Gulf Coast seafood. The second is a complex of multi-drug resistance (MDR) patterns, in 
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which isolates were susceptible to agents from at least five CLSI classes. These MDR 
patterns were seen in isolates from travellers to Hispaniola (n=37), South Asia (n=35), 
Africa (n=2), and in several domestically acquired cases that were not linked to Gulf Coast 
Seafood (n=3). All were resistant to nalidixic acid, and all but four (two from travellers to 
Bangladesh in 2007 and 2011, one traveller to India in 2008, and one traveller to Pakistan in 
2010) were susceptible to tetracycline. The third pattern complex included isolates resistant 
to furazolidone alone (one was also resistant to nalidixic acid); it was seen in the 13 isolates 
from travellers to Southeast Asia as well as in seven domestically acquired cases that were 
not linked to Gulf Coast seafood. Antimicrobial susceptibility testing was also conducted on 
the isolate of V. cholerae O139; it was resistant to nalidixic acid, streptomycin, sulfisoxazole 
and trimethoprim-sulfamethoxazole, but was susceptible to furazolidone and the other 
agents in the panel.
DISCUSSION
Our review of cholera in the United States from 2001 to 2011 confirms the truth of the 
saying that even rare and apparently exotic infectious diseases are just an airplane ride away. 
Less than a month after cholera was first noted in Haiti in October 2010, cases associated 
with that outbreak had been diagnosed in the United States [24, 25]. In 2011, more than 
twice as many US cases of cholera were associated with travel to Haiti than had been 
reported from all sources in any year over the previous decade, reminiscent of the pattern 
seen in the early 1990s with the outbreaks of cholera in Latin America [8]. Cholera has now 
become endemic in Haiti and has been imported from Hispaniola to Canada, Spain, 
Venezuela, and possibly Cuba [21, 26]. Endemic transmission of cholera persists in the 
Dominican Republic and Cuba, as in Haiti, and poses a continued threat of travel-associated 
cases, particularly to the United States and the rest of the Western hemisphere.
Travel to Asia and consumption of raw or undercooked seafood continue to be sources of 
cholera in the United States [7–9]. Cases associated with travel to other cholera-affected 
countries, primarily in Asia, were reported throughout the review period, with no sign of 
decrease. The incubation period of cholera is short – typically 12 h to 2 days – so it is likely 
that additional cases occur while travellers are abroad and are not captured by this 
surveillance system. Long travel times from Africa and Asia may mean that cases in 
travellers to these areas are especially likely not to be diagnosed in the United States. 
Although sanitation standards in the United States make sustained transmission unlikely, 
cholera and other waterborne diseases are likely to continue to be imported until safe water 
and adequate sanitation are available to all worldwide. Several cases were associated with 
consumption in the United States of raw or undercooked seafood, including not only seafood 
harvested from the Gulf Coast, a focus of V. cholerae O1 first described in the late 1970s 
[10], but also imported seafood.
Different states have had markedly different experiences with cholera. Most cases associated 
with travel to Hispaniola were reported from just two states, New York and Florida. As 
these are the states with the largest populations of Haitians and Dominicans – Florida 
(251963, 46%), New York (135836, 25%) – this pattern is not surprising, but it is a reminder 
of the need for culturally and linguistically appropriate medical care and public health 
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response [27]. In Florida, for example, the state health department produced educational 
materials on cholera in Haitian Creole for patients and their contacts that greatly facilitated 
response. Cholera cases associated with travel to other countries, by contrast, were reported 
by 22 states, with no more than eight cases from any state. Most of these patients had 
travelled to South Asia or Southeast Asia; only two cases were associated with travel to 
Africa, although many African countries have been hit hard by cholera in recent years [28, 
29]. The relative lack of US cases associated with travel to Africa likely reflects, at least in 
part, low numbers of travellers, relative to other destinations. A pattern of relatively low 
numbers of cases – but high risk per traveller – has been reported for other enteric infections 
[30]. Domestically acquired cholera predominantly affected the Gulf Coast states of 
Louisiana and Texas, as in years past. In sum, health-care providers and public health 
authorities in all states should be prepared to diagnose, treat, and respond to cases of 
cholera.
Strategies for prevention of cholera in US residents depend to a great extent on the exposure 
scenario. Of patients with travel-associated cholera, 62% travelled to visit friends or 
relatives (VFR) in another country. These types of travellers are less likely than others to 
seek medical consultation before travel and may also perceive less risk from food and water 
while travelling [30, 31]; they can be hard to reach with prevention messages. Other 
travellers reported travelling for tourism, business, or medical missions or other relief work. 
Notably, since their risk of exposure may be particularly high, these types of travellers are 
relatively likely to receive pre-travel medical consultation, which can stress the importance 
of safe water and food in preventing not only cholera, but many other enteric infections as 
well. There are currently two WHO-prequalified vaccines available outside the United 
States. Although no cholera vaccines are currently available in the United States, a cholera 
vaccine intended for US travellers is in development [32]; its use would require a pre-travel 
healthcare visit. Although we have no data on the proportion of patients who sought pre-
travel care, among those for whom information on reason for travel was available and who 
were not residents of another country, only 24% were not travelling to visit friends or 
relatives. For a vaccine to have optimal impact, strategies to reach VFR travelers would be 
needed. Regarding the potential impact of a vaccine for travellers, it is important to note that 
US surveillance captures only cases diagnosed in the United States. Finally, prevention of 
domestically acquired cholera lies squarely in the realm of food safety; the great majority of 
cases are associated with consumption of raw or undercooked seafood.
Cholera has a well-deserved reputation as a severe, often fatal disease, but prompt and 
appropriate therapy can all but eliminate fatalities. In our review, 98% of patients reported 
diarrhoea; 62% of those with information on hospitalization were hospitalized. Although 
none died, several developed severe complications including acute renal failure, 
cardiopulmonary arrest, and shock. These severe complications from profound dehydration 
speak to the need for clinicians to be aware of cholera and prepared to treat it appropriately 
[33, 34]. Importantly, because dehydration progresses rapidly after onset of diarrhoea, 
patients must be able to access care within a few hours of symptom onset. If a traveller is en 
route or far from healthcare, cholera gravis can lead to death before a patient reaches a 
treatment facility. CDC has advised that pre-packaged oral rehydration salts be carried on 
international flights to address this need [35]. Treatment with antimicrobial agents is 
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adjunctive but can shorten the duration of symptoms and V. cholerae shedding [36]. Several 
public health organizations recommend doxycycline (an antimicrobial in the tetracycline 
class) as first-line therapy and ciprofloxacin (an antimicrobial in the quinolone class; 
resistance to nalidixic acid correlates with decreased susceptibility to ciprofloxacin) as an 
alternative. In our review, isolates from patients whose source of cholera was travel to 
Southeast Asia or Gulf Coast seafood were susceptible to these agents (except for one 
isolate from a patient with domestically acquired cholera who ate seafood of unknown 
source, which was resistant to nalidixic acid). Isolates from patients who had travelled to 
Hispaniola, South Asia, and Africa, as well as some who acquired cholera domestically from 
sources other than Gulf Coast seafood were uniformly resistant to nalidixic acid, but most 
were susceptible to tetracycline. Within sources of exposure, these resistance patterns did 
not vary over the period of our review. Macrolide antibiotics are also recommended by some 
organizations as an alternative agent, but macrolides are not included in the panel of agents 
tested.
Healthcare providers in the United States should consider cholera in patients, especially 
adults, with severe watery diarrhoea. The level of suspicion should be heightened for 
patients with a history of international travel to cholera-endemic regions or of consuming 
raw or undercooked seafood from the Gulf Coast or elsewhere. Cholera is most often 
diagnosed by stool culture on thiosulfate citrate bile salts sucrose (TCBS) medium, which in 
most settings must be specifically requested by the clinician. State and local public health 
laboratories should send all V. cholerae isolates to CDC for confirmatory testing and 
subtyping by PFGE or, as they become available, newer methods such as whole genome 
sequencing. CDC can also measure vibriocidal and anti-cholera toxin antibodies in serum.
As with other notifiable infections, surveillance data on cholera in the United States is 
limited both by under-diagnosis and by under-reporting. Patients may not seek medical care 
for mild cases, and health-care providers may not make a specific diagnosis even in severe 
cases. Reporting by providers and clinical laboratories to states is passive and by state health 
departments to COVIS is both passive and voluntary. However, under-reporting per se is 
unlikely to be a major source of bias; a recent comparison of COVIS data to FoodNet active 
surveillance data showed similar patterns of incidence and trends in Vibrio infections in both 
systems. Nonetheless, our data should be viewed as a minimal estimate of cholera in the 
United States.
In summary, this review of US cholera early in the 21st century describes another important 
chapter in the history of cholera in the United States. This history includes, in the late 1970s, 
the discovery of the Gulf Coast strain of V. cholerae O1 [10]; in the early 1990s, a surge of 
cases associated with epidemic cholera in Latin America [37–39]; in the late 1990s and early 
2000s, a relative lull during which most cases were associated with travel to Asia [7, 8]. 
Now, in the second decade of the new millennium, we are witnessing a marked increase in 
cases associated with the new epidemic in Hispaniola. Throughout, prevention has depended 
on basic standards of safe water, sanitation, and food safety. To the extent that the United 
States can maintain these standards at home and foster their development abroad, it can both 
protect its own population and contribute to efforts to improve public health in other 
countries [4].
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States and US territories reporting cholera cases, 2001–2011 (n=111 cases).
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Number of cholera cases by year, and by source 2001–2011, United States (n=111 cases).
LOHARIKAR et al. Page 11

























LOHARIKAR et al. Page 12
Table 1
Cholera cases by age group and source, 2001–2011, United States (n=111 cases)
Age group (years) Travel-associated (n=90) Domestically acquired (n=20) Unknown source (n=1) Total (n=111)
<1 0 0 0 0
1 1 0 0 1
2–4 5 1 0 6
5–9 2 0 0 2
10–19 7 0 0 7
20–29 12 2 1 15
30–64 50 13 0 63
≥65 13 4 0 17




























































































































































































































































































































































































































































































































































































































































































































































































Epidemiol Infect. Author manuscript; available in PMC 2015 October 22.
